Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERI-China: Post-marketing observational study of vericiguat in Chinese HFrEF patients
CTR20230182Phase 4Completed
- Sponsor
- Bayer
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vericiguat in heart failure with reduced ejection fraction (HFrEF), sponsored by Bayer. Started Apr 2023; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on CTR20230182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230182.